Merck & Co., Inc.

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:33 2024-04-23 pm EDT			After market 06:00:05 pm
126.9 ^USD	-0.05%		128	+0.88%

Apr. 19	Merck Says Health Canada Approved Keytruda Plus Fluoropyrimidine, Platinum-Containing-Chemotherapy for Gastric Cancer	MT
Apr. 19	BMO Capital Adjusts Price Target on Merck & Company to $148 From $132	MT

MERCK & CO INC : JP Morgan remains Neutral

September 30, 2019 at 03:24 am EDT

JP Morgan's research confirms his advice and maintains his neutral opinion on the stock.. The target price is unchanged and still at USD 89.

Latest news about Merck & Co., Inc.

Merck Says Health Canada Approved Keytruda Plus Fluoropyrimidine, Platinum-Containing-Chemotherapy for Gastric Cancer	Apr. 19	MT
BMO Capital Adjusts Price Target on Merck & Company to $148 From $132	Apr. 19	MT
Leerink Partners Raises Merck's Price Target to $134 From $129	Apr. 19	MT
Zacks Adjusts Price Target on Merck & Company to $132 From $128	Apr. 15	MT
Merck & Co Receives a Shareholder Proposal from The Bahnsen Family Trust	Apr. 11	CI
Merck & Co Receives a Shareholder Proposal from National Legal and Policy Center	Apr. 11	CI
Merck & Co Receives a Shareholder Proposal from Kenneth Steiner	Apr. 11	CI
Transcript : Merck & Co., Inc. Presents at Ginkgo's Annual Ferment Conference 2024, Apr-11-2024 09:55 AM	Apr. 11
S&P 500 ends slightly higher as markets brace for inflation data, earnings	Apr. 09	RE
Wall St backs down as markets brace for inflation data, earnings	Apr. 09	RE
Moderna Shares Rise Following Positive Results of Head and Neck Cancer Vaccine in Early Study	Apr. 09	MT
Moderna jumps as personalized cancer vaccine shows benefit in early study	Apr. 09	RE
Berenberg Raises Price Target on Merck & Company to $143 From $140, Maintains Buy Rating	Apr. 08	MT
Geneos cancer vaccine shrinks liver tumors in small trial	Apr. 07	RE
Boehringer to lay off salespeople as Humira biosimilar sales lag	Apr. 05	RE
Boehringer to lay off salespeople as Humira biosimilar sales lag	Apr. 04	RE
Merck & Co., Inc. acquired Abceutics, Inc. for approximately $210 million.	Apr. 04	CI
Merck Starts Phase 3 Clinical Trial of Potential Lung Cancer Combination Therapy	Apr. 04	MT
Merck: launches phase III trial in lung cancer	Apr. 04	CF
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA®? (pembrolizumab) for First-Line Treatment of Certain Patients with Metastatic Non-Small Cell Lung Cancer	Apr. 04	CI
Merck, Daiichi Sankyo Dose First Person in Phase 2/3 Trial of Raludotatug Deruxtecan to Treat Ovarian Cancer	Apr. 03	MT
Merck: 1st patient in raludotatug study	Apr. 03	CF
US takes next step in Medicare drug price negotiations with pharma companies	Apr. 02	RE
Robert Davis, Merck CEO: Another obesity drug?	Mar. 28	MT
Merck: new indication approved for Keytruda in Europe	Mar. 28	CF

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (18%); - sale of animal health products (9.4%); - other (2.9%). Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).

Sector

Pharmaceuticals

Calendar

2024-04-25 - Q1 2024 Earnings Release

Related indices

Dow Jones Industrial , S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Merck & Co., Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

126.9 USD

Average target price

137.6 USD

Spread / Average Target

+8.38%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
MERCK & CO., INC.	+16.38%	322B
ELI LILLY AND COMPANY	+27.92%	659B
NOVO NORDISK A/S	+27.68%	557B
JOHNSON & JOHNSON	-4.59%	359B
ABBVIE INC.	+9.39%	297B
ASTRAZENECA PLC	+6.30%	215B
NOVARTIS AG	+4.80%	210B
ROCHE HOLDING AG	-6.05%	200B
PFIZER, INC.	-8.58%	149B
AMGEN INC.	-4.99%	146B

Other Pharmaceuticals

Merck & Co., Inc.

Equities

MRK

US58933Y1055

Pharmaceuticals

MERCK & CO INC : JP Morgan remains Neutral

Latest news about Merck & Co., Inc.

Chart Merck & Co., Inc.

Company Profile

Income Statement Evolution

Ratings for Merck & Co., Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals